What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?

Cancer Research

Volumn 62, Issue 7, 2002, Pages 1931-1934

  Rak, Janusz ^a   Yu, Joanne L ^b   Kerbel, Robert S ^b   Coomber, Brenda L ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; THROMBOSPONDIN 1; VASCULOTROPIN;

ADAPTATION; ANGIOGENESIS; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CELL SUBPOPULATION; ENDOTHELIUM CELL; GENE MUTATION; HYPOXIA; MALIGNANT TRANSFORMATION; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRESS; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 0036531949     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. The hallmarks of cancer
2. Clinical applications of research on angiogenesis
3. Tumor angiogenesis: Therapeutic implications
4. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
5. A cancer therapy resistant to resistance
6. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
7. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy
8. Targeted drugs take centre stage at US cancer meeting
9. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment
10. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
11. The clonal evolution of tumor cell populations
12. Cancer: Looking outside the genome
13. A genetic model for colorectal tumorigenesis
14. How tumors become angiogenic
15. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
16. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
17. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
18. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis
19. Inhibition of apoptosis during development of colorectal cancer
20. Proliferation, cell cycle and apoptosis in cancer
21. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
22. Effect of p53 status on tumor response to antiangiogenic therapy
23. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression
24. Constitutive expression of hypoxia inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation
25. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
26. Heterogeneous vascular dependence of tumor cell populations
27. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls
28. Normalizing tumor vaculature with anti-angiogenic therapy: A new paradigm for combination therapy
29. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours
30. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors
31. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer
32. Angiogenesis in pituitary adenomas and the normal pituitary gland
33. Prognostic relevance of microvessel density in colorectal tumours
34. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
35. Farnesyltransferase and geranylgeranyitransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
36. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
37. 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
38. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
39. Genetic heterogeneity of angiogenesis in mice